JBC
5-[(E)-(3-carboxy-4-oxidanyl-phenyl)diazenyl]-2-oxidanyl-benzoic acid
Created: | 2021-05-12 |
Last modified: | 2022-01-19 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 32 |
Chiral Atom Count | 0 |
Bond Count | 33 |
Aromatic Bond Count | 12 |
Chemical Component Summary | |
---|---|
Name | 5-[(E)-(3-carboxy-4-oxidanyl-phenyl)diazenyl]-2-oxidanyl-benzoic acid |
Systematic Name (OpenEye OEToolkits) | 5-[(~{E})-(3-carboxy-4-oxidanyl-phenyl)diazenyl]-2-oxidanyl-benzoic acid |
Formula | C14 H10 N2 O6 |
Molecular Weight | 302.239 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | CACTVS | 3.385 | OC(=O)c1cc(ccc1O)N=Nc2ccc(O)c(c2)C(O)=O |
SMILES | OpenEye OEToolkits | 2.0.7 | c1cc(c(cc1N=Nc2ccc(c(c2)C(=O)O)O)C(=O)O)O |
Canonical SMILES | CACTVS | 3.385 | OC(=O)c1cc(ccc1O)N=Nc2ccc(O)c(c2)C(O)=O |
Canonical SMILES | OpenEye OEToolkits | 2.0.7 | c1cc(c(cc1/N=N/c2ccc(c(c2)C(=O)O)O)C(=O)O)O |
InChI | InChI | 1.03 | InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+ |
InChIKey | InChI | 1.03 | QQBDLJCYGRGAKP-FOCLMDBBSA-N |
Drug Info: DrugBank
DrugBank ID | DB01250 |
---|---|
Name | Olsalazine |
Groups | approved |
Description | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA).[A257063] It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine].[A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon.[A257078] Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase, subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene.[A257063] Olsalazine is used in the treatment of ulcerative colitis.[L45023,L45151] |
Synonyms |
|
Brand Names | Dipentum |
Indication | In the US, olsalazine is indicated for the maintenance of remission of ulcerative colitis in adult patients who are intolerant to [sulfasalazine].[L45023] In Canada, it is used in the treatment of acute ulcerative colitis of mild to moderate severity, with or without the concomitant use of steroids. It is also indicated for the long-term maintenance of patients with ulcerative colitis in remission.[L45151] |
Categories |
|
ATC-Code | A07EC03 |
CAS number | 15722-48-2 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Human Cyclooxygenases | MSRSLLLWFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFG... | unknown | inhibitor |
Thiopurine S-methyltransferase | MDGTRTSLDIEEYSDTEVQKNQVLTLEEWQDKWVNGKTAFHQEQGHQLLK... | unknown | inhibitor |
Xanthine dehydrogenase/oxidase | MTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGEGGCGA... | unknown | inhibitor |
Solute carrier family 2, facilitated glucose transporter member 9 | MARKQNRNSKELGLVPLTDDTSHAGPPGPGRALLECDHLRSGVPGGRRRK... | unknown | downregulator |
Solute carrier family 22 member 6 | MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCR... | unknown | upregulator |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682